Positive impactResults
Sun Pharma shares gain despite Q2 profit slips 36% YoY | Should you buy, sell or hold? What brokerage says, target price
Mint 1 hr ago·1 Nov 2026, 12:11 pm
Sun Pharma’s stock edged higher by less than 1% even though its September‑quarter net profit fell sharply, dropping about 36% year‑on‑year to roughly ₹1,988 crore. The company still managed to grow revenue by close to 12%, reaching around ₹16,200 crore, helped by stronger sales in India and its innovative medicines portfolio.
The profit decline was largely driven by higher expenses tied to ongoing U.S. litigation and costs associated with the recent Organon acquisition. While top‑line growth signals continued demand, the margin pressure from these one‑off items is a key focus for investors assessing the company’s earnings quality.
Going forward, market participants will be watching the resolution of the U.S. legal cases, the integration progress of Organon, and any guidance on future profit margins or revenue growth that could influence analyst target prices.
Excerpt from Mint
Sun Pharma shares rose 0.87% despite a 36.4% year-on-year drop in September-quarter net profit to ₹ 1,988.5 crore. Revenue increased 11.9% to ₹ 16,198.7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings. Sun Pharmaceutical Industries…Read the original at Mint
Affected stocks
Bullish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Sun Pharmaceutical Industries (SUNPHARMA).
- Category: Results.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update for Sun Pharmaceutical Industries worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
